Eli Lilly and CompanyLLYNYSE
Loading
Cash Generation ExpandingExpanding
Percentile Rank100
3Y CAGR+24.9%
5Y CAGR+14.9%
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

3Y CAGR
+24.9%/yr
vs +16.4%/yr prior
5Y CAGR
+14.9%/yr
Recent acceleration
Acceleration
+8.5pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$8.97B+2065.6%
2024$414.30M+113.1%
2023$-3.15B-168.5%
2022$4.60B-14.6%
2021$5.39B+20.5%
2020$4.47B+28.3%
2019$3.48B+39.0%
2018$2.51B-27.4%
2017$3.45B-8.2%
2016$3.76B-